Autologous haematopoietic SCT with PBSCs is regularly used to restore BM function in patients with multiple myeloma or lymphoma after myeloablative chemotherapy. Twenty-eight experts from the European Group for Blood and Marrow Transplantation developed a position statement on the best approaches to mobilising PBSCs and on possibilities of optimising graft yields in patients who mobilise poorly. Choosing the appropriate mobilisation regimen, based on patients' disease stage and condition, and optimising the apheresis protocol can improve mobilisation outcomes. Several factors may influence mobilisation outcomes, including older age, a more advanced disease stage, the type of prior chemotherapy (e.g., fludarabine or melphalan), prior irradiation or a higher number of prior treatment lines. The most robust predictive factor for poor PBSC collection is the CD34(+) cell count in PB before apheresis. Determination of the CD34(+) cell count in PB before apheresis helps to identify patients at risk of poor PBSC collection and allows pre-emptive intervention to rescue mobilisation in these patients. Such a proactive approach might help to overcome deficiencies in stem cell mobilisation and offers a rationale for the use of novel mobilisation agents.

Addenbrooke's Hospital Cambridge UK

American University of Beirut Beirut Lebanon

Beatson West of Scotland Cancer Centre Glasgow UK

Catalan Institute of Oncology L'Hospitalet de Llobregat Barcelona Spain

Chaim Sheba Medical Center Tel Hashomer Israel

Cremona Hospital Cremona Italy

Department of Haematology AZ Sint Jan Brugge Oostende Belgium

Department of Haematology Saint Antoine Hospital Paris France

Department of Haematooncology University Hospital Ostrava Ostrava Czech Republic

Department of Medicine 5 Heidelberg University Heidelberg Germany

EORTC Headquarters Brussels Belgium

Imperial College London London UK

Institut Paoli Calmettes and Inserm CBT 510 Marseille France

Institute of Children Haematology and Transplantation n a R Gorbacheva St Petersburg State Pavlov Medical University St Petersburg Russia

King Faisal Specialist Hospital and Research Centre Riyadh Saudi Arabi

Maastricht University Medical Centre Maastricht The Netherlands

Medical University Vienna Vienna Austria

National Research Centre for Haematology Moscow Russia

Quantitative Health Sciences Cleveland Clinic Cleveland OH USA

St Istvan and St Laszlo Hospital Budapest Hungary

The Medical University of Warsaw Warsaw Poland

University Hospital Coimbra Coimbra Portugal

University Hospital Cologne Cologne Germany

University Hospital Dubrava Zagreb Croatia

University Hospital Hamburg Eppendorf Hamburg Germany

University of Genoa Genoa Italy

Zobrazit více v PubMed

J Biol Regul Homeost Agents. 2003 Jul-Sep;17(3):247-53 PubMed

Bone Marrow Transplant. 2012 Apr;47(4):483-7 PubMed

Bone Marrow Transplant. 2012 Nov;47(11):1403-8 PubMed

Biol Blood Marrow Transplant. 2010 Apr;16(4):490-9 PubMed

Biol Blood Marrow Transplant. 2009 Dec;15(12):1578-86 PubMed

Leukemia. 2011 Oct;25(10):1627-31 PubMed

Leukemia. 2008 Jun;22(6):1282-4 PubMed

Br J Cancer. 2000 Jan;82(2):278-82 PubMed

Ann Hematol. 2009 Jul;88(7):673-80 PubMed

J Clin Oncol. 1999 Dec;17(12):3776-85 PubMed

Br J Haematol. 2001 Aug;114(2):319-26 PubMed

Biol Blood Marrow Transplant. 2011 Jan;17(1):141-6 PubMed

Exp Hematol. 2011 Jul;39(7):723-9 PubMed

Leukemia. 2012 May;26(5):1119-22 PubMed

Bone Marrow Transplant. 2011 Jul;46(7):943-9 PubMed

Bone Marrow Transplant. 2009 Feb;43(3):197-206 PubMed

Bone Marrow Transplant. 2009 Feb;43(3):181-95 PubMed

Cytometry B Clin Cytom. 2012 Jan;82(1):9-17 PubMed

Bone Marrow Transplant. 2010 Feb;45(2):269-75 PubMed

Clin Lymphoma Myeloma. 2007 Jan;7(4):315-8 PubMed

Eur J Haematol. 2011 Jun;86(6):488-95 PubMed

Haematologica. 2008 Nov;93(11):1739-42 PubMed

Bone Marrow Transplant. 2009 Feb;43(3):223-8 PubMed

Transfusion. 2005 Feb;45(2):248-53 PubMed

Transfusion. 2014 Feb;54(2):331-9 PubMed

Bone Marrow Transplant. 2009 Apr;43(8):619-25 PubMed

Bone Marrow Transplant. 2008 Feb;41(4):331-8 PubMed

Bone Marrow Transplant. 2003 Sep;32(6):563-7 PubMed

Transfusion. 2012 Mar;52(3):542-8 PubMed

Expert Opin Biol Ther. 2011 Sep;11(9):1241-8 PubMed

Cytotherapy. 2011 Apr;13(4):459-66 PubMed

Haematologica. 2006 May;91(5 Suppl):ECR08 PubMed

J Clin Apher. 2009;24(4):134-40 PubMed

Bone Marrow Transplant. 2012 Dec;47(12):1526-9 PubMed

Br J Haematol. 2008 Apr;141(2):244-8 PubMed

Transfusion. 2013 May;53(5):1024-32 PubMed

Transfus Apher Sci. 2007 Feb;36(1):95-101 PubMed

Bone Marrow Transplant. 2009 Jan;43(2):101-5 PubMed

Bone Marrow Transplant. 2011 Apr;46(4):523-8 PubMed

Curr Pharm Des. 2008;14(20):1950-61 PubMed

Blood. 2009 Jun 4;113(23):5720-6 PubMed

Bone Marrow Transplant. 2011 Jan;46(1):44-51 PubMed

Haematologica. 2005 Feb;90(2):225-31 PubMed

Biol Blood Marrow Transplant. 2013 Jan;19(1):87-93 PubMed

Bone Marrow Transplant. 2011 Jun;46(6):806-12 PubMed

J Clin Oncol. 1998 Apr;16(4):1547-53 PubMed

Leuk Lymphoma. 2011 Sep;52(9):1711-9 PubMed

Haematologica. 2007 Aug;92(8):1083-90 PubMed

Bone Marrow Transplant. 2011 Jan;46(1):59-63 PubMed

Biol Blood Marrow Transplant. 2008 Sep;14(9):1045-1056 PubMed

Biol Blood Marrow Transplant. 2009 Jun;15(6):718-23 PubMed

Bone Marrow Transplant. 2012 Mar;47(3):342-51 PubMed

Blood. 1996 Feb 15;87(4):1625-34 PubMed

Biol Blood Marrow Transplant. 2008 Oct;14(10):1118-1124 PubMed

Bone Marrow Transplant. 2011 Mar;46(3):356-63 PubMed

Blood. 2000 Apr 1;95(7):2234-9 PubMed

Leuk Lymphoma. 2009 Mar;50(3):463-5 PubMed

Bone Marrow Transplant. 2010 Jan;45(1):63-8 PubMed

Am J Hematol. 2012 Jan;87(1):1-4 PubMed

J Clin Oncol. 2009 Oct 1;27(28):4767-73 PubMed

Biol Blood Marrow Transplant. 2008 Nov;14(11):1253-61 PubMed

Transfusion. 2010 Nov;50(11):2432-46 PubMed

Cytotherapy. 2012 Aug;14(7):823-9 PubMed

Bone Marrow Transplant. 2011 Jul;46(7):936-42 PubMed

J Clin Oncol. 2003 Oct 15;21(20):3744-53 PubMed

Bone Marrow Transplant. 2010 Jan;45(1):39-47 PubMed

Bone Marrow Transplant. 2011 Jan;46(1):52-8 PubMed

Leukemia. 2008 Jun;22(6):1280-1; author reply 1281-2 PubMed

Transfus Apher Sci. 2009 Aug;41(1):33-7 PubMed

Haematologica. 2008 Mar;93(3):405-12 PubMed

J Cancer Res Clin Oncol. 2005 Apr;131(4):214-8 PubMed

J Clin Apher. 2012;27(2):64-74 PubMed

Leuk Lymphoma. 2003 Jun;44(6):997-1000 PubMed

Exp Hematol. 2009 Nov;37(11):1266-73 PubMed

Bone Marrow Transplant. 2012 Jul;47(7):906-23 PubMed

Bone Marrow Transplant. 2001 Jul;28(2):207-12 PubMed

Blood. 1995 Nov 15;86(10):3961-9 PubMed

Bone Marrow Transplant. 1997 Aug;20(3):211-7 PubMed

Leukemia. 2007 Sep;21(9):2035-42 PubMed

Transfus Apher Sci. 2008 Dec;39(3):187-92 PubMed

Biol Blood Marrow Transplant. 2008 Jul;14(7):795-8 PubMed

Br J Haematol. 2010 Sep;150(6):647-62 PubMed

Bone Marrow Transplant. 2012 Apr;47(4):488-93 PubMed

J Cancer Res Clin Oncol. 2009 Apr;135(4):637-42 PubMed

Bone Marrow Transplant. 2002 Feb;29(4):285-90 PubMed

Am J Hematol. 2009 Dec;84(12):809-14 PubMed

Transfusion. 2012 Apr;52(4):906-14 PubMed

Cytotherapy. 2009;11(8):992-1001 PubMed

Biol Blood Marrow Transplant. 2011 Jul;17(7):943-55 PubMed

Transfusion. 2012 Aug;52(8):1785-91 PubMed

Biol Blood Marrow Transplant. 2012 Feb;18(2):241-9 PubMed

J Clin Oncol. 2002 May 1;20(9):2344-52 PubMed

Bone Marrow Transplant. 2011 Jan;46(1):64-9 PubMed

J Clin Oncol. 2001 Sep 1;19(17):3771-9 PubMed

Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor